About Us
The Department of Genetic Medicine at Weill Cornell leads a dynamic and innovative translational research program, advancing diverse fields such as Genetic Therapy and Personalized Medicine.
The Department of Genetic Medicine at Weill Cornell leads a dynamic and innovative translational research program, advancing diverse fields such as Genetic Therapy and Personalized Medicine.
Our translational research program aims to leverage our expertise in genetic therapies and personalized medicine to develop clinical solutions that target the molecular causes of human diseases.
The Department of Genetic Medicine advances treatments and diagnostics through diverse clinical trials, including drug testing and research to better understand diseases.
The Belfer Gene Therapy Core Facility (BGTCF) is a cutting-edge genetic medicine research facility.
The Department of Genetic Medicine at Weill Cornell leads a dynamic and innovative translational research program, advancing diverse fields such as Genetic Therapy and Personalized Medicine.
Our translational research program aims to leverage our expertise in genetic therapies and personalized medicine to develop clinical solutions that target the molecular causes of human diseases.
The Department of Genetic Medicine advances treatments and diagnostics through diverse clinical trials, including drug testing and research to better understand diseases.
The Belfer Gene Therapy Core Facility (BGTCF) is a cutting-edge genetic medicine research facility.
The Office of Academic Integration (OVPAI) has awarded $750,000 in seed grants to 10 studies ranging from refugee health and legal rights, to a vaccine treating fentanyl addiction and overdose, to pancreatic cancer and antibiotic tolerance.
This year’s awardees represent faculty collaborations across five colleges and schools, and 18 departments and divisions across the Cornell Ithaca campus and Weill Cornell Medicine and Cornell Tech in New York City.
Designed to catalyze collaborative research interactions among Cornell faculty based in Ithaca and New York City, OVPAI provides funding opportunities that foster transdisciplinary, multi-investigator programs that aim to be competitive for support from federal funders and major foundations.
Since it was established in 2018, OVPAI has already spawned collaborative programs that have garnered five times as much funding as Cornell’s initial investment.
“By creating synergies among Cornell faculty and research units, laboratories have leveraged the research expertise across all campuses to transform individual projects into larger programs with increased impact and visibility,” said Dr. Gary Koretzky, vice provost for academic integration. “These seed grants have already demonstrated their impact in providing investigators with the opportunity to explore new and innovative collaborations that otherwise would not have been possible.”
The 2021 Multi-Investigator Seed Grant RFA is now open and faculty from all disciplines are encouraged to apply. Two funding tracks, of $75,000 and $100,000, are available. Letters of intent are due by March 26, followed by full applications due in October.
The 2020 Multi-Investigator Seed Grant projects: